ArticlePloS one2025
Transcriptional profiling identification of inflammatory signaling pathways in ulcerative colitis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic type of inflammatory bowel disease (IBD). This study identified core genes and pathways involved in UC by performing transcriptional profiling of colon biopsies from UC patients and healthy controls using data from the Gene Expression Omnibus (GEO) database. A total of 202 samples, including 129 UC patients and 73 healthy controls, were analyzed, measuring the expression of 40,991 genes using a 44K formatted microarray. Differential gene expression (DGE) analysis and gene set enrichment analysis (GSEA) identified several biomarkers potentially involved in UC development. PLCB3 was significantly downregulated, which suggested its role in maintaining intestinal homeostasis. In contrast, DUOX2 was upregulated, which indicated its involvement in the inflammatory response and oxidative stress. Pathway analysis revealed that PLCB3 is associated with lipid metabolism, NOD-like receptor signaling, and NF-κB signaling pathways, while DUOX2 is linked to reactive oxygen species production and chemokine signaling. The interplay between PLCB3 and DUOX2 suggests their combined impact on inflammatory processes in UC. These insights into the molecular mechanisms underlying UC identify key genes and pathways that could serve as potential targets for diagnostic and therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.